Semaglutide Dosing: Units, Titration & Genetic Factors

Last reviewed: May 29, 2026

Last updated: May 29, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Semaglutide dosing typically begins at 0.25 mg (equivalent to 2.5 units in some formulations) once weekly, with gradual increases every seven days. Standard maintenance ranges from 0.5 to 2.4 mg per week, though doses vary based on individual tolerance and clinical goals.

Dose selection is more complex than a single number—your baseline metabolic health, insulin sensitivity, gastrointestinal tolerance, and genetic predispositions all influence how your body responds. PlexusDx focuses on precision wellness by helping you understand these individual factors before and during treatment.

Standard Titration Schedule and Unit Equivalents

Semaglutide follows a standardized four-week titration protocol designed to minimize gastrointestinal side effects and allow metabolic adaptation. Each weekly dose increases by 0.25 mg: week one at 0.25 mg, week two at 0.5 mg, week three at 0.75 mg, and week four at 1.0 mg maintenance.

Unit measurements vary by formulation. Compounded semaglutide concentrations differ from branded formulations, so always verify your specific dose with your provider or pharmacist. The compounding pharmacy provides clear unit markings on syringes to ensure accurate administration and safety.

Biomarkers and Metabolic Factors That Influence Dose Response

Individual dose response depends partly on baseline metabolic markers—fasting glucose, HbA1c, triglycerides, and insulin resistance indices—that reflect how your body processes glucose and metabolizes peptides. Patients with higher insulin resistance or metabolic dysfunction may require different titration timing than those with preserved insulin sensitivity.

Biomarker	Relevance to Dose Response
Fasting Glucose (mg/dL)	Baseline hyperglycemia may require faster titration; tight control may necessitate slower increases to avoid hypoglycemia.
HbA1c (%)	Higher baseline HbA1c may correlate with greater metabolic benefit at standard doses; lower levels may need dose adjustment.
Insulin Resistance (HOMA-IR)	High HOMA-IR may predict better response to GLP-1 effects on beta-cell function and insulin secretion at therapeutic doses.
Triglycerides (mg/dL)	Elevated triglycerides often indicate insulin resistance; may influence titration pace and gastrointestinal tolerance thresholds.

Genetic Variants Associated with Peptide Pathway Response

Genetic variants in GLP-1 receptor (GLP1R) and glucose-dependent insulinotropic polypeptide receptor (GIPR) genes influence how effectively semaglutide engages its target and how your body metabolizes it. The PlexusDx Precision Peptide Genetic Test evaluates key variants such as GIPR rs1800437 to provide context on peptide pathway predispositions.

These genetic differences may explain why some patients achieve significant metabolic benefit at lower doses while others require higher maintenance doses for similar clinical outcomes. Your genetic profile does not dictate your exact response but may help guide a more informed dose-titration conversation with your healthcare provider.

Safety Considerations, Contraindications, and Provider Guidance

Semaglutide is not appropriate for all patients. Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, severe gastroparesis, and uncontrolled diabetic retinopathy. Dose escalation requires ongoing clinical assessment to monitor for pancreatitis, acute kidney injury, and gastrointestinal complications.

Your provider should evaluate your full medical history, current medications, and organ function before initiating therapy and at each dose increase. Do not self-adjust doses based on internet recommendations—compounded semaglutide requires a valid prescription and ongoing clinical oversight to ensure safety and efficacy.

How PlexusDx Supports a More Personalized Approach

PlexusDx genetic testing may help provide context about how your individual peptide pathways function—specifically how your GLP-1 receptor and related glucose-sensing systems are encoded. This information, interpreted with a qualified healthcare provider, can support more personalized discussions about why standard doses might require adjustment for your unique physiology.

The Precision Peptide Genetic Test reveals predispositions in four key pathways: GLP1R signaling, GIPR function, energy homeostasis (FTO gene), and melanocortin appetite regulation (MC4R gene). These variants do not predict exact medication response but may clarify whether your genetic background suggests potential for varying dose requirements or metabolic phenotypes.

Understanding your genetic peptide profile, combined with baseline biomarkers and clinical history, enables a more informed conversation with your provider about optimal starting dose, titration pace, and long-term maintenance targets. This precision approach reduces trial-and-error and helps align dosing strategy with your individual biology.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral is $349/mo month-to-month, or from $279/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Why do syringe units not mean the same thing across every semaglutide product?

Because unit measurements vary by formulation, and compounded semaglutide concentrations differ from branded ones. The article says the same number of units can correspond to a different milligram amount depending on the preparation, so a figure taken from one product cannot be carried across to another. It directs readers to verify their own dose with the prescribing provider or pharmacist instead of converting it themselves.

Which lab markers does this article link to how a person responds to treatment?

It lists fasting glucose, HbA1c, HOMA-IR as an insulin resistance index, and triglycerides. The article describes these as reflecting how the body processes glucose and metabolizes peptides, and says people with higher insulin resistance or metabolic dysfunction may follow a different timeline than those with preserved insulin sensitivity. All of it is framed as context for a provider's assessment.

Why does this article warn readers against changing their own dose?

Because compounded semaglutide requires a valid prescription and ongoing clinical oversight, and the article says not to self-adjust based on internet recommendations. It notes that every escalation step calls for clinical assessment to monitor for pancreatitis, acute kidney injury, and gastrointestinal complications. A provider should review medical history, current medications, and organ function before therapy begins and at each change.

Does this article name gastroparesis or retinopathy among reasons to avoid semaglutide?

Yes. Severe gastroparesis and uncontrolled diabetic retinopathy both appear in its contraindication list, alongside a personal or family history of medullary thyroid carcinoma and multiple endocrine neoplasia type 2. The article presents these as things to settle before therapy begins rather than problems to manage afterward. A provider should confirm none of them applies before any prescription is written.

What role does the compounding pharmacy play in getting the measurement right?

The article says the compounding pharmacy supplies clear unit markings on syringes so the amount administered is accurate. That matters because concentrations differ between compounded and branded preparations, which makes the marking on your own syringe the reference point rather than a number found online. Any question about what those markings mean is routed back to your provider or pharmacist.

Related Reading

• Semaglutide Starting Dose
• Semaglutide Dosing
• What Genetic Factors Influence Vulnerability To Food Allergies
• What Genetic Factors Increase Acl Injury Risk How Can Plexusdx Testing Help

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.